雪莲系列微创手术手套
Search documents
瑞京“雪莲”系列新品发布 以创新筑牢医护防护线
Zhong Guo Jing Ji Wang· 2025-12-01 04:14
Core Viewpoint - Beijing Ruijing Latex Products Co., Ltd. launched its "Snow Lotus" series of micro-invasive surgical gloves, emphasizing innovation and responsiveness to healthcare needs during a recent product release and industry dialogue event [1][6]. Group 1: Product Launch and Features - The "Snow Lotus" series was unveiled in collaboration with experts from top medical institutions, highlighting its core advantages such as enhanced skin-friendliness and improved anti-slip features [3][6]. - The product development team showcased the upgraded materials and processes, focusing on the dual enhancement of protective performance and user experience [3][6]. Group 2: Market Strategy and Future Plans - The company is implementing a "dual circulation" strategy, with 60% of its home and industrial hand protection products exported in 2023, aiming to optimize this to 50% in 2024, while increasing market shares in Europe and South America [7]. - Plans to leverage the Beijing Economic Development Zone's platform to connect with JD.com for domestic market expansion and to enter new markets in Central Asia through cross-border e-commerce partnerships are underway [7]. Group 3: Industry Engagement and Collaboration - The event facilitated direct interaction between healthcare professionals and the company, allowing for real-time feedback on product comfort and protective capabilities, fostering a collaborative environment [3][6]. - Experts from various medical fields emphasized the need for protective products to meet safety standards while being user-friendly, leading to initial cooperation agreements with medical device distributors [6][7]. Group 4: Social Responsibility and Commitment - The company plans to initiate a grassroots medical "protection empowerment program" to enhance protective standards in western and remote areas through product donations and technology transfer [9]. - The commitment to global healthcare is underscored by the desire to provide high-quality medical products that reflect Chinese innovation and manufacturing capabilities [9].